3 months ago
2
China’s medicine regulator has ordered a halt to the import, sale and usage of a cause utilized to treat dementia associated with Alzheimer’s illness made by India’s Sun Pharmaceutical Industries, according to an announcement posted connected Monday (January 26, 2026).
The National Medical Products Administration said a caller distant inspection recovered shortcomings successful the company’s accumulation processes, including successful the prevention of contamination anfulfilmentd the prime absorption department’s fulfillment of duties.
The assemblage banned the merchantability of Sun Pharma’s rivastigmine hydrogen tartrate capsules.
A spokesperson for Sun Pharma, India’s largest drugmaker by revenue, did not instantly respond to a petition for comment.
In 2024, the U.S. Food and Drug Administration issued a informing missive to Sun Pharma alleging “significant violations” of “current bully manufacturing practice” regulations for pharmaceuticals made astatine the aforesaid accumulation tract successful India, according to the U.S. regulator’s website.
Rivastigmine capsules person been utilized arsenic a dementia attraction successful China, 1 survey showed.
